Biotronik

Biotronik

Berlin, Germany· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Biotronik is a global, privately-held leader in active implantable medical devices, specializing in cardiovascular and neuromodulation therapies. Its core strength lies in innovative technologies like its DX single-lead ICD system with atrial sensing, Closed Loop Stimulation (CLS), and comprehensive remote patient monitoring via its Home Monitoring ecosystem. The company is in a commercial stage, generating revenue from a broad portfolio of approved devices, and competes directly with larger players like Medtronic, Abbott, and Boston Scientific in the CRM market.

CardiovascularChronic Pain

Technology Platform

Proprietary active implantable device platforms including DX Technology (single-lead ICD with atrial sensing), Closed Loop Stimulation (CLS) physiological rate-response algorithm, and an integrated remote patient monitoring/digital health ecosystem (Home Monitoring, Patient App).

Opportunities

The growing global burden of cardiovascular disease and the shift towards value-based, remote patient monitoring create significant opportunities for Biotronik's integrated device-and-digital solutions.
Its differentiated technologies, like DX for atrial monitoring, address specific unmet needs in large patient subsets within the CRM market.

Risk Factors

Biotronik faces intense competition from larger, better-resourced public medtech companies.
Regulatory hurdles and cost-containment pressures in global healthcare systems could delay adoption or limit reimbursement for its innovative devices.
Technological disruption from new entrants in adjacent fields also poses a threat.

Competitive Landscape

Biotronik competes in the highly concentrated Cardiac Rhythm Management (CRM) market, dominated by Medtronic, Abbott, and Boston Scientific. It differentiates through niche technologies like its DX system and CLS algorithm, and its strong focus on integrated remote monitoring. In Neuromodulation, it competes with players like Nevro, Boston Scientific, and Abbott.